Pandemic Best Regulatory Practices: An Urgent Need in the COVID-19 Pandemic
- PMID: 32498131
- PMCID: PMC7300901
- DOI: 10.1002/cpt.1932
Pandemic Best Regulatory Practices: An Urgent Need in the COVID-19 Pandemic
Abstract
As large numbers of candidate drugs and vaccines for potential use in the coronavirus disease 2019 (COVID-19) pandemic are being investigated, medicine regulators globally must now make urgent, informed, contextually risk-1based decisions regarding clinical trials and marketing authorizations. They must do this with the flexibility demanded by the pandemic while maintaining their core risk assessment and public safety functions. We lay out the critical role of regulators in the current crisis and offer eight "pandemic best regulatory practices." These should support both the regulatory public heath imperative and assure timely patient access to effective, safe, quality products worldwide during this emergency-thus contributing to ending this pandemic as quickly, effectively, and safely as possible.
© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
The authors declared no competing interests for this work.
References
-
- International Council for Harmonisation <https://www.ich.org/>. Accessed May 21, 2020.
-
- International Medical Device Regulators Forum <http://www.imdrf.org/>. Accessed May 21, 2020.
-
- International Coalition of Medicines Regulatory Authorities <http://www.icmra.info/drupal/en/home>. Accessed May 21, 2020.
-
- World Health Organization . International Conference of Drug Regulatory Authorities <https://www.who.int/medicines/areas/quality_safety/regulation_legis...>. Accessed May 21, 2020.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
